Novartis breast cancer drug gets FDA fast track, takes on Pfizer : foxnews

referring to foxnews

Novartis breast cancer drug gets FDA fast track, takes on Pfizer

Novartis breast cancer drug gets FDA fast track, takes on Pfizer

The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug.Ribociclib, or LEE011, was also accepted by the European Medicines Agency (EMA) for review in use with letrozole in the same patient population, the company said in a statement on Tuesday.The U.S. priority review of LEE011 is based on data presented last month at a cancer conference.It showed patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer who took ribociclib with letrozole were 44 percent less likely to see their disease progress or to die versus those on letrozole alone.


besides wcjb

Man with breast cancer speaks out

Man with breast cancer speaks out

GAINESVILLE, Fla. -- Breast Cancer Awareness Month just ended, and one man battling the disease wanted people to be aware that men can also get breast cancer.The Gainesville man said his diagnosis came as a surprise.Researchers say one in eight women in America have breast cancer.Dr. Allison Grow, oncologist at North Florida Regional Cancer Center said, "It's about 1% as common in men, about 2,500 cases diagnosed last year in the United States."


in the same way sciencedaily

Silencing SIRT2, a sirtuin enzyme, reduces malignancy in deadly breast cancer subtype -- ScienceDaily

Silencing SIRT2, a sirtuin enzyme, reduces malignancy in deadly breast cancer subtype -- ScienceDaily

Silencing SIRT2, a member of the sirtuin family of enzymes, reduces the invasiveness of basal-like breast cancer cells in culture and inhibits tumor growth in mice, according to new research led by scientists from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts in Boston.The absence of SIRT2 appears to accelerate the degradation of Slug, a transcription factor that has previously been implicated in tumor progression and metastasis.The findings, published online in Cell Reports on Oct. 25, reveal underlying molecular mechanisms and potential new approaches to treat one of the deadliest breast cancer subtypes."Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form.


in the same way news-medical

NUS researchers identify molecular switch that makes breast cancer cells more aggressive

NUS researchers identify molecular switch that makes breast cancer cells more aggressive

By controlling the molecular switch, scientists could potentially make aggressive cancers more sensitive to conventional drugs and improve treatment outcomesA team of scientists from the National University of Singapore (NUS) has established novel insights into the relationship between breast cancer tumour intracellular redox environment and the cancer cells' ability to become invasive.The study by Dr Alan Prem Kumar from the Cancer Science Institute of Singapore (CSI Singapore) at NUS and NUS Yong Loo Lin School of Medicine, together with Professor Shazib Pervaiz and Associate Professor Marie-Veronique Clement from NUS Yong Loo Lin School of Medicine, found that high levels of Manganese Superoxide Dismutase (MnSOD), a key enzyme involved in regulating the cellular redox milieu, has a role to play in causing breast cancer cells to turn aggressive, especially in triple negative breast cancer subtype tumours.These aggressive cells are able to invade other sites in the body, resulting in secondary tumours."Our group's work over the years has highlighted the critical role of cancer cells' oxidative metabolism in drug resistance and cell survival.


coupled with foxnews

Woman claims she lost job after breast cancer reveal

Woman claims she lost job after breast cancer reveal

A New Jersey woman who is suing her former employer claims she was fired one day after revealing she had been diagnosed with breast cancer.NJ.com reported that Carmela Flynn, 49, filed the lawsuit against the partners at November & Nunnink in Bergen County Superior Court.The lawsuit names supervising partners Celine Y. November and Laura A. Nunnink.According to court papers filed last month, Flynn also alleges that the partners denied her unemployment benefits because she would not sign an agreement declaring that she would not sue the business.